A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice

Fred R. Sattler, Stephen Paolucci, John W. Kreider, Roger L. Ladda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PLC/PRF/5 is a human liver cancer cell line which synthesizes hepatitis B virus surface antigen (HBsAg). These cells produced tumor in 6 of 8 (75%) congenitally athymic nude mice at 13 of 28 subcutaneous injection sites and in 13 of 14 (93%) mice inoculated intraperitoneally. Tumors were successfully transplanted to 4 of 6 additional nude mice. Tumor growth was rapid. Growth of cephalad tumors was significantly greater than for caudal tumors (0.39 mm/day versus 0.28 mm/day). Microscopic examination of tumors showed moderately well-differentiated hepatocellular carcinoma. Foci of identical cells were present in pulmonary veins in 7 of 14 tumor-bearing animals. Tumor cell karyotype was identical with that of PLC/PRF/5 cells. In addition, HBsAg was detectable in high titer in animals with extensive tumor. Biological features of PLC/PRF/5-induced tumors in nude mice appeared to closely resemble human hepatocellular carcinoma. Moreover, HBsAg may provide a marker of tumor growth.

Original languageEnglish (US)
Pages (from-to)381-389
Number of pages9
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number4
DOIs
StatePublished - Apr 1982

Fingerprint

Hepatitis B Surface Antigens
Hepatitis B virus
Nude Mice
Hepatocellular Carcinoma
Neoplasm Metastasis
Cell Line
Lung
Neoplasms
Growth
Pulmonary Veins
Subcutaneous Injections
Liver Neoplasms
Tumor Biomarkers
Karyotype

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Sattler, Fred R. ; Paolucci, Stephen ; Kreider, John W. ; Ladda, Roger L. / A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice. In: European Journal of Cancer and Clinical Oncology. 1982 ; Vol. 18, No. 4. pp. 381-389.
@article{0cd09ff3b6b345fb9a22d94c158b995b,
title = "A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice",
abstract = "PLC/PRF/5 is a human liver cancer cell line which synthesizes hepatitis B virus surface antigen (HBsAg). These cells produced tumor in 6 of 8 (75{\%}) congenitally athymic nude mice at 13 of 28 subcutaneous injection sites and in 13 of 14 (93{\%}) mice inoculated intraperitoneally. Tumors were successfully transplanted to 4 of 6 additional nude mice. Tumor growth was rapid. Growth of cephalad tumors was significantly greater than for caudal tumors (0.39 mm/day versus 0.28 mm/day). Microscopic examination of tumors showed moderately well-differentiated hepatocellular carcinoma. Foci of identical cells were present in pulmonary veins in 7 of 14 tumor-bearing animals. Tumor cell karyotype was identical with that of PLC/PRF/5 cells. In addition, HBsAg was detectable in high titer in animals with extensive tumor. Biological features of PLC/PRF/5-induced tumors in nude mice appeared to closely resemble human hepatocellular carcinoma. Moreover, HBsAg may provide a marker of tumor growth.",
author = "Sattler, {Fred R.} and Stephen Paolucci and Kreider, {John W.} and Ladda, {Roger L.}",
year = "1982",
month = "4",
doi = "10.1016/0277-5379(82)90010-4",
language = "English (US)",
volume = "18",
pages = "381--389",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "4",

}

A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice. / Sattler, Fred R.; Paolucci, Stephen; Kreider, John W.; Ladda, Roger L.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 4, 04.1982, p. 381-389.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A human hepatoma cell line (PLC/PRF/5) produces lung metastases and secretes HBsAg in nude mice

AU - Sattler, Fred R.

AU - Paolucci, Stephen

AU - Kreider, John W.

AU - Ladda, Roger L.

PY - 1982/4

Y1 - 1982/4

N2 - PLC/PRF/5 is a human liver cancer cell line which synthesizes hepatitis B virus surface antigen (HBsAg). These cells produced tumor in 6 of 8 (75%) congenitally athymic nude mice at 13 of 28 subcutaneous injection sites and in 13 of 14 (93%) mice inoculated intraperitoneally. Tumors were successfully transplanted to 4 of 6 additional nude mice. Tumor growth was rapid. Growth of cephalad tumors was significantly greater than for caudal tumors (0.39 mm/day versus 0.28 mm/day). Microscopic examination of tumors showed moderately well-differentiated hepatocellular carcinoma. Foci of identical cells were present in pulmonary veins in 7 of 14 tumor-bearing animals. Tumor cell karyotype was identical with that of PLC/PRF/5 cells. In addition, HBsAg was detectable in high titer in animals with extensive tumor. Biological features of PLC/PRF/5-induced tumors in nude mice appeared to closely resemble human hepatocellular carcinoma. Moreover, HBsAg may provide a marker of tumor growth.

AB - PLC/PRF/5 is a human liver cancer cell line which synthesizes hepatitis B virus surface antigen (HBsAg). These cells produced tumor in 6 of 8 (75%) congenitally athymic nude mice at 13 of 28 subcutaneous injection sites and in 13 of 14 (93%) mice inoculated intraperitoneally. Tumors were successfully transplanted to 4 of 6 additional nude mice. Tumor growth was rapid. Growth of cephalad tumors was significantly greater than for caudal tumors (0.39 mm/day versus 0.28 mm/day). Microscopic examination of tumors showed moderately well-differentiated hepatocellular carcinoma. Foci of identical cells were present in pulmonary veins in 7 of 14 tumor-bearing animals. Tumor cell karyotype was identical with that of PLC/PRF/5 cells. In addition, HBsAg was detectable in high titer in animals with extensive tumor. Biological features of PLC/PRF/5-induced tumors in nude mice appeared to closely resemble human hepatocellular carcinoma. Moreover, HBsAg may provide a marker of tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=0019993087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019993087&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90010-4

DO - 10.1016/0277-5379(82)90010-4

M3 - Article

C2 - 6889516

AN - SCOPUS:0019993087

VL - 18

SP - 381

EP - 389

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 4

ER -